These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26291129)

  • 21. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways.
    Xiang W; Sng C; Lam YH; Kok ZH; Linn YC; Neo SY; Siew YY; Singh D; Koh HL; Chuah C
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
    Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins.
    Colecchia D; Strambi A; Sanzone S; Iavarone C; Rossi M; Dall'Armi C; Piccioni F; Verrotti di Pianella A; Chiariello M
    Autophagy; 2012 Dec; 8(12):1724-40. PubMed ID: 22948227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels.
    Pan Y; Lou J; Wang H; An N; Chen H; Zhang Q; Du X
    Blood Cells Mol Dis; 2018 Nov; 73():38-44. PubMed ID: 30224298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
    Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
    Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
    Hiroki H; Ishii Y; Piao J; Namikawa Y; Masutani M; Honda H; Akahane K; Inukai T; Morio T; Takagi M
    Sci Rep; 2023 May; 13(1):7588. PubMed ID: 37165001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib.
    Mancini M; Leo E; Campi V; Castagnetti F; Zazzeroni L; Gugliotta G; Santucci MA; Martinelli G
    Cell Signal; 2014 Aug; 26(8):1690-7. PubMed ID: 24747551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
    Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
    Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.